Solid-state delivery systems for lipophilic actives.
MTRX Pharmaceutical develops platform-enabled oral and topical candidate formats designed to improve the developability, usability and translational potential of cannabinoids, botanical actives and other poorly soluble molecules, with Autoimmune Disorders as a lead R&D focus.
A technology company first. Applications second.
Solid self-emulsifying systems
Designed to convert challenging lipophilic actives into solid-state delivery formats with improved formulation relevance and development optionality.
Candidate formats
Oral capsule, topical lotion/cream and partner-selected lipophilic active programs can be organized as R&D assets, led by Autoimmune Disorders and atopic dermatitis-oriented topical development.
Licensing and co-development
Built for strategic discussions with pharma, medical cannabis, specialty dermatology, CDMO, investment and regional commercialization partners.
Bridging lipophilic actives to solid-state delivery.
Conversion methodology
Platform processing converts oily or difficult lipophilic actives into solid delivery systems.
Delivery architecture
Solid-state self-emulsifying architecture supports oral and topical candidate formats.
Partner development
Candidate formats can move into feasibility, PK screening, clinical-test-article design and partner-led development.
Platform-enabled R&D candidates.
| Asset | Technology profile | Target area | Status |
|---|---|---|---|
| MTRX-101 | MTRX-CBD-OC-25/100 Oral CBD solid-dose capsule series | Oral cannabinoid therapeutics / dose-ranging | Partner-ready |
| MTRX-201 | MTRX-CBD-DERM-8 Topical CBD dermatology program | Atopic dermatitis / skin barrier / inflammatory dermatoses | Prototype-ready |
| MTRX-301 | MTRX-CX-OC-Series THC/CBD combination capsule platform | Pain / CNS / supportive care exploratory models | Formulation-ready |
Build the next MTRX program.
Explore licensing, co-development, regional commercialization, clinical-test-article generation or strategic acquisition discussions.